Kailera Therapeutics, Inc. SEC filings KLRA

Kailera Therapeutics, Inc. has 64 filings in SEC EDGAR's recent list, going back to Dec 19, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Kailera Therapeutics, Inc. SEC filings
Form Description Filed Period
10-Q Quarterly report Nov 4, 2026 Sep 30, 2026
8-K Current report
Results of operations
Nov 4, 2026 Nov 4, 2026
10-Q Quarterly report Aug 12, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 12, 2026 Aug 12, 2026
10-Q Quarterly report May 26, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 26, 2026 May 26, 2026
8-K Current report
Bylaw or fiscal year change, Other events
Apr 20, 2026 Apr 20, 2026
424B4 Prospectus Apr 17, 2026 —
S-8 Employee stock plan registration Apr 17, 2026 —
EFFECT Filing Apr 16, 2026 —
S-1MEF Filing Apr 16, 2026 —
CERT Filing Apr 15, 2026 —
8-A12B Filing Apr 14, 2026 —
S-1/A Amended registration statement Apr 13, 2026 —
S-1 Registration statement Mar 27, 2026 —
DRS/A Filing Feb 11, 2026 —
DRS Filing Dec 19, 2025 —

Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KLRA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
, Emerging growth company
SEC CIK
2096997

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.